Cytek Biosciences Stock Performance
| CTKB Stock | USD 4.06 0.05 1.25% |
On a scale of 0 to 100, Cytek Biosciences holds a performance score of 16. The firm shows a Beta (market volatility) of 0.12, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cytek Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cytek Biosciences is expected to be smaller as well. Please check Cytek Biosciences' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Cytek Biosciences' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cytek Biosciences are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating forward-looking signals, Cytek Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.49) | Five Day Return (0.74) | Year To Date Return (38.51) | Ten Year Return (78.46) | All Time Return (78.46) |
1 | Cytek Biosciences, Inc. Elevates Cell Analysis with New Aurora Evo System | 05/30/2025 |
2 | Acquisition by Hardison Don M of 15706 shares of Cytek Biosciences subject to Rule 16b-3 | 06/09/2025 |
3 | Acquisition by Imper Vera of 23809 shares of Cytek Biosciences at 3.07 subject to Rule 16b-3 | 06/18/2025 |
4 | Cytek Biosciences Elects New Directors at Annual Meeting - TipRanks | 06/24/2025 |
5 | Acuitas Investments LLC Buys New Stake in Cytek Biosciences, Inc. | 07/02/2025 |
6 | Disposition of 14733 shares by Wenbin Jiang of Cytek Biosciences subject to Rule 16b-3 | 07/16/2025 |
7 | Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025 | 07/23/2025 |
8 | How does Cytek Biosciences Inc. compare to its industry peers - Stock Market Updates For Beginners - jammulinksnews.com | 07/31/2025 |
9 | Cytek Biosciences Reports Second Quarter 2025 Financial Results | 08/06/2025 |
10 | Cytek Biosciences Second Quarter 2025 Earnings EPS Beats Expectations, Revenues Lag | 08/08/2025 |
11 | Analysts Opinions Are Mixed on These Healthcare Stocks Cytek Biosciences , Natera and Warby Parker - The Globe and Mail | 08/11/2025 |
12 | Acquisition by Wenbin Jiang of 19334 shares of Cytek Biosciences subject to Rule 16b-3 | 08/14/2025 |
13 | Cytek Biosciences, Inc. Stock Catapults 26 percent Though Its Price And Business Still Lag The Industry | 08/15/2025 |
| Begin Period Cash Flow | 167.6 M | |
| Total Cashflows From Investing Activities | -83 M |
Cytek Biosciences Relative Risk vs. Return Landscape
If you would invest 245.00 in Cytek Biosciences on May 22, 2025 and sell it today you would earn a total of 161.00 from holding Cytek Biosciences or generate 65.71% return on investment over 90 days. Cytek Biosciences is currently generating 0.9269% in daily expected returns and assumes 4.4839% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Cytek, and 82% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytek Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytek Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytek Biosciences, and traders can use it to determine the average amount a Cytek Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2067
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CTKB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.48 actual daily | 40 60% of assets are more volatile |
Expected Return
| 0.93 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Cytek Biosciences is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytek Biosciences by adding it to a well-diversified portfolio.
Cytek Biosciences Fundamentals Growth
Cytek Stock prices reflect investors' perceptions of the future prospects and financial health of Cytek Biosciences, and Cytek Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytek Stock performance.
| Return On Equity | -0.0167 | ||||
| Return On Asset | -0.0377 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 278.19 M | ||||
| Shares Outstanding | 127.22 M | ||||
| Price To Book | 1.37 X | ||||
| Price To Sales | 2.63 X | ||||
| Revenue | 200.45 M | ||||
| Gross Profit | 106.68 M | ||||
| EBITDA | (10.03 M) | ||||
| Net Income | (6.02 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 17.02 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.97 X | ||||
| Cash Flow From Operations | 25.38 M | ||||
| Earnings Per Share | (0.05) X | ||||
| Market Capitalization | 516.53 M | ||||
| Total Asset | 499.5 M | ||||
| Retained Earnings | (35.2 M) | ||||
| Working Capital | 328.78 M | ||||
About Cytek Biosciences Performance
By analyzing Cytek Biosciences' fundamental ratios, stakeholders can gain valuable insights into Cytek Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cytek Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cytek Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 179.31 | 256.50 | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.02) | (0.02) |
Things to note about Cytek Biosciences performance evaluation
Checking the ongoing alerts about Cytek Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytek Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytek Biosciences appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 106.68 M. | |
| About 63.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Cytek Biosciences, Inc. Stock Catapults 26 percent Though Its Price And Business Still Lag The Industry |
- Analyzing Cytek Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytek Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cytek Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytek Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytek Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytek Biosciences' stock. These opinions can provide insight into Cytek Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |